Long-form writing.

Andrew Samann·June 25, 2026·13-minute read

The most expensive way to build a GMP facility is to design the building first and bolt compliance on afterward. The right first deliverable isn't a floor plan — it's a User Requirements Specification (URS): a document-controlled brief that makes the facility compliant by design, with every room, flow, and pressure cascade traceable to a documented requirement. It's what you walk into your architect with — and it deliberately stops where Design Qualification and commissioning begin.

Andrew Samann·June 24, 2026·14-minute read

Equipment does not become GMP by being well-built — it becomes GMP-suitable when it ships with the design evidence and controlled documentation a regulated buyer needs to qualify it (URS, DQ, FAT/SAT, IQ, OQ, PQ per Annex 15). For an OEM selling into Europe, the machine is only half the product; the other half is the qualification package, and it is the half that closes the sale. What an equipment manufacturer must deliver, where the manufacturer's job ends and the buyer's begins, and why 'CE marked' is not 'GMP-ready.'

Andrew Samann & Kate Evans, PhD·June 24, 2026·15-minute read

Europe's medical cannabis market has grown up — and as a recent Business of Cannabis essay argued, its supply chain must follow, to EU-GMP standards. But EU GMP is the destination, not the road. The road is ICH: EudraLex Volume 4 adopts the ICH guidelines wholesale — Part II is Q7, the quality system is Q10, risk management is Q9, plus the Q1 stability series and Q2(R2)/Q14 for analytical methods. Build to ICH and you build once to the bar every fragmented European market enforces. Where the bridge is genuinely EU-specific (the Qualified Person, GDP, national labelling) — and how a cultivator becomes EU-ready without ripping the system out and starting over.

Andrew Samann & Kate Evans, PhD·June 20, 2026·18-minute read

EU GMP and FDA GMP agree on 70–80% of substance — but export programs fail in the 20% that diverges. A clause-level comparison of EudraLex Volume 4 and 21 CFR 210/211: the Qualified Person who legally certifies every batch, principle vs. prescription, the ICH Q10 PQS, Annex 1 contamination control, the Site Master File, mutual recognition limits, the distinct EU GDP regime, and the food/supplement carve-outs (Parts 111/117). With the build-once strategy for supplying both markets.

Andrew Samann·June 19, 2026·12-minute read

DEA Schedule III, Virginia's new adult-use market, FDA, EU export — they look like four separate compliance problems but are one. Every regime reduces to the same two moves: set specifications (your Critical Quality and Safety Attributes), then run a risk assessment against them under ICH Q9 Quality Risk Management. The universal pathway that lets operators build once, satisfy whichever regulator shows up, and start before the rulebook is even final.

Andrew Samann·June 1, 2026·36-minute read

Operators pursuing CTM supply, EU export, or IND/NDA filings should build ONE integrated quality system to ICH Q10 / EU-GMP / 21 CFR 211 at the highest common bar — not three siloed systems. The standards overlap 70-80%; the deltas are knowable; sequential builds cost ~2.2× the integrated approach. Strategic thesis, integrated standard stack, twelve system pillars, leadership self-diagnostic.

Andrew Samann·June 1, 2026·14-minute read

Diagnostic walk-through of the seven specific operational and regulatory pains state-licensed cannabis manufacturers are facing in the federal-pathway window — DEA Form 225/224 readiness, Public Interest defense, the Single Convention buy/sell-back, the Schedule III federal overlay, the Part 211 pivot for pharma-pathway operators, 280E and dual-license production segregation, and EU export readiness. Intended for C-suite mapping the next 60-180 days.

Andrew Samann·May 27, 2026·10-minute read

The April 2026 rescheduling reset what compliance means for cannabis manufacturers. The strategic overview — DEA registration by ~June 27, redeploying 280E savings, Quality by Design rigor, and what international export under § 1312.30 actually unlocks.

Andrew Samann·May 27, 2026·45-minute read

Step-by-step transition primer for cultivators applying for DEA registration under 21 CFR § 1301.13(k). Eligibility gate, document pack, application mechanics, public-interest defense memo, the Single Convention buy/sell-back, international export structural limits, and a complete pre-submission checklist. Free, behind a lightweight email gate.